Zobrazeno 1 - 10
of 1 577
pro vyhledávání: '"Vonoprazan"'
Publikováno v:
Clinical Endoscopy, Vol 57, Iss 4, Pp 417-423 (2024)
Since the introduction of vonoprazan, a potassium-competitive acid blocker (P-CAB), it has been demonstrated to reversibly inhibit gastric acid secretion by engaging in potassium-competitive ionic binding to H+/K+-ATPase. In contrast, proton pump inh
Externí odkaz:
https://doaj.org/article/b4e6fcd031d0415a9bc70403e5fb2236
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background In Chinese healthcare settings, drug selection decisions are predominantly influenced by the Pharmacy & Therapeutics Committee (PTC). This study evaluates two recently introduced potassium-competitive acid blockers, vonoprazan (VP
Externí odkaz:
https://doaj.org/article/6150a3f8d757480b928ac82d73a895ea
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-11 (2024)
Abstract A new, sensitive, and rapid isocratic reversed phase chromatographic method (RP-HPLC–UV) was developed for simultaneous separation of two newly co-formulated antiulcer mixtures; Amoxicillin, Vonoprazan and Clarithromycin [Mixture (I)], and
Externí odkaz:
https://doaj.org/article/f2105d28a383498ca06e8093512a6e28
Publikováno v:
Frontiers in Nutrition, Vol 11 (2024)
Background and aimsVonoprazan, a novel acid suppressant, has been employed in the treatment of peptic ulcer disease in recent years. However, the efficacy and safety of vonoprazan versus proton-pump inhibitors remains controversial. To address this g
Externí odkaz:
https://doaj.org/article/2df6900ed9da46ac94e02fee27ecb7ed
Publikováno v:
Gastroenterology Insights, Vol 15, Iss 2, Pp 386-395 (2024)
Background: Vonoprazan-based triple therapy has recently been reported as being more effective than proton pump inhibitors for the eradication of Helicobacter pylori (H. pylori), but it is apparent that the eradication rate could be further improved.
Externí odkaz:
https://doaj.org/article/bc78739e70b542509fa6469949191a0f
Autor:
Yuji Urabe, Hideki Ishikawa, Akira Ishikawa, Shingo Ishiguro, Kazuki Ishibashi, Koji Arihiro, Michihiro Mutoh, Shiro Oka
Publikováno v:
Case Reports in Gastroenterology, Vol 18, Iss 1, Pp 293-298 (2024)
Introduction: Familial adenomatous polyposis (FAP), a hereditary disorder of the gastrointestinal tract, is an autosomal dominant inherited condition caused by germline mutations in the adenomatous polyposis coli (APC) gene. It is characterized by th
Externí odkaz:
https://doaj.org/article/47528158d32949ff9e145062caa6a565
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-13 (2024)
Abstract Helicobacter pylori has a big sway when peptic ulcers are concerned. For its eradication, different protocols have been approved. Among which, the tripartite therapy protocol which embraces vonoprazan as potassium competitive acid blocker in
Externí odkaz:
https://doaj.org/article/790af9b8a780491a92c971e01fc60171
Autor:
Shun Sasaki, Kazuhiro Ota, Makoto Sanomura, Yosuke Mori, Hironori Tanaka, Akitoshi Hakoda, Noriaki Sugawara, Taro Iwatsubo, Yuki Hirata, Kazuki Kakimoto, Hideaki Morita, Wataru Nagamatsu, Masaaki Hoshiga, Toshihisa Takeuchi, Kazuhide Higuchi, Hiroki Nishikawa
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Although proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) are useful in peptic ulcer prevention, their efficacy in preventing other gastrointestinal bleeding remains unclear. This study aimed to identify
Externí odkaz:
https://doaj.org/article/f50ca14043de4b42b8c4ab13b9f5972a
Autor:
Chen Chen, Daya Zhang, Shimei Huang, Fan Zeng, Da Li, Xiaodong Zhang, Runxiang Chen, Shiju Chen, Jun Wang, Feihu Bai
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Objective To compare the potential efficacy and safety of dual therapy and quadruple therapy with vonoprazan (VPZ) as well as the standard quadruple therapy of proton pump inhibitor (PPI) for the eradication of Helicobacter pylori (Hp) infec
Externí odkaz:
https://doaj.org/article/2d8e2d9c24334d37a9bc1c68094016d5
Publikováno v:
Xin yixue, Vol 55, Iss 3, Pp 204-207 (2024)
Objective To evaluate clinical efficacy of the combination of Vonoprazan and high-dose Amoxicillin in the initial eradication treatment of Helicobacter pylori （Hp）. Methods Select 200 patients with Hp infection who have not undergone Hp eradicati
Externí odkaz:
https://doaj.org/article/20199126f7784a01a6a7dea32cfd6084